On February 4, 2019 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), reported that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at the BIO CEO & Investor Conference February 11-12, 2019 (Press release, Onconova, FEB 4, 2019, https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-inc-present-corporate-update-bio-ceo [SID1234533027]). Dr. Fruchtman and members of management will be available for 1×1 meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details: 1:15 – 1:30p EST Monday, February 11th
Gramercy, 7th Floor
Marriott Marquis 1535 Broadway, New York, NY 10036
A webcast of the presentation will be available one hour after the conclusion of the live event at http://www.veracast.com/webcasts/bio/ceoinvestor2019/71117204463.cfm and can also be accessed via View Source on the Company’s website after the event.